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Abstract 
Essential fatty acids are structural components of all biological membranes and form the environment for 
membrane receptors, ion channels, and enzymes. Dietary linoleic acid is metabolized by delta-6-desaturase 
to gamma-Iinolenic acid (GLA). Through several further metabolic steps, GLA is eventually converted to 
series-1 prostaglandins, thromboxanes, and other molecules involved in regulating the moment-to-moment 
function of various physiological processes. For example, prostaglandins interact with dopamine 
neurotransmission. The biochemistry and physiology of essential fatty acids are reviewed, with attention to 
possible implications for behavior. Delta-6-desaturase deficiency has been hypothesized to be one cause of 
attention-deficit hyperactivity disorder (ADHD). To explore this possibility, we examined the correlations of 
serum lipids and behavior in a double-blind crossover comparison of GLA, d-amphetamine, and placebo in 
16 boys (ages 6-12) with ADHD. Looking at the fatty-acid components of serum triglycerides across 
treatment conditions, we found that higher scores for behavior problems correlated with lower levels of GLA 
(for each of four behavioral ratings, p < 0.015) but not with its precursor, linoleic acid. This is compatible 
with a metabolic bottleneck at delta-6-desaturase being related to some ADHD symptoms. These preliminary 
findings are consistent with the possibility that fatty-acid intake or metabolism may influence behavior, at 
least in children with ADHD, and could conceivably modulate the effects of psychopharmacological 
treatment. This study must be considered exploratory and heuristic, and more definitive studies are needed to 
examine the possible relevance of fatty-acid metabolism to psychiatric disorders. 
Several possible mechanisms may link essential fatty-acid metabolism to behavior. These 
potential connections include not only the effects of general body metabolism on brain function, 
but also the structural need for polyunsaturated fatty acids in neuronal membranes and the 
influence of these fatty acids and their metabolic products on neurotransmitter production, release, 
and effects. 
This article will review the biochemistry and physiology of essential fatty acids, consider 
some suggestive animal behavior findings, focus more specifically on possible implications of 
gamma-linolenic acid (GLA) for attention-deficit hyperactivity disorder (ADHD), and finally 
present some relevant pilot data. 
Background Biochemistry of Essential Fatty Acids 
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directly from the essential fatty-acid precursor in each tissue and quickly inactivated, thus 
regulating the moment-to-moment function of various physiological processes (Horrobin and 
Manku 1990). There are interactions with other essential nutrients: zinc, ascorbate (vitamin C), 
and niacin (B3) are coenzymes with cyclooxygenase, and series-2 prostaglandins are believed to 
be necessary for zinc absorption from the gut (Song and Adham 1980). 
Other eicosanoids include the leukotrienes (formed by lipoxygenase) and the epoxy-acids 
(formed by cytochrome P-450, which is inhibited by some psychotropic drugs and induced by 
others). 
Essential Fatty-Acid Activity and Neurons 
The concept of essential fatty-acid activity includes both the effects of the fatty acids 
themselves and the effects of their metabolites, mainly eicosanoids. Essential fatty acids are 
essential constituents of all membranes from skin and gut to neuronal cell membranes, and affect 
plasticity and permeability. They form the environment for membrane proteins such as receptors, 
ion channels, and enzymes. A high proportion of unsaturation in a membrane reduces steroid 
binding to receptors in that membrane (Horrobin and Manku 1990, Mitsuhashi et al. 1986). 
Unsaturated fatty acids can block cell-membrane chloride channels (Hwang et al. 1990), activate 
K+ channels (Kim and Clapham 1989, Ordway et al. 1989), and activate the d isoform of protein 
kinase C (McPhail et al. 1984). Crane and Greenwood (1987) found dietary fat to influence 
neuronal monoamine oxidase activity (high level of dietary polyunsaturates suppressed 
mitochondrial MAO). 
Long-term potentiation of synaptic transmission in the hippocampus is a persistent 
enhancement of synaptic efficacy precipitated by brief, high frequency, tetanic glutamate-pathway 
activation (Bliss et al. 1990). It has been implicated in learning and memory. Glutamate 
depolarizes the postsynaptic membrane, relieving the Mg2+ blockade of the NMDA receptor ion 
channel and letting calcium enter to initiate the cascade that persistently enhances synaptic 
transmission. A current mechanism hypothesis is that arachidonic acid is released from 
postsynaptic membranes and diffuses to the presynaptic terminal, where it facilitates glutamate 
release (Wolfe and Horrocks 1993). 
Prostaglandins (eicosanoid derivatives of essential fatty acids) have many interactions with 
dopamine and norepinephrine, the catecholamine neurotransmitters that have been implicated in 
ADHD and other psychiatric and behavioral disorders. For example, dopamine (D2) receptor 
stimulation potentiates release of arachidonic acid for PGE2 synthesis; high levels of D2 receptors 
and PGE2 in such CNS areas as hypothalamus and amygdala suggest a modulatory role for PGE2 
in dopamine transmission (Di Marzo and Piomelli 1992). Prostaglandins and norepinephrine act 
antagonistically on Purkinje cell firing; PGE2 reduces neostriatal and cortical release of dopamine 
and norepinephrine; dopamine stimulates phospholipase-A mobilization of prostaglandin 
precursors from ester bonds; the binding of biogenic amines to postsynaptic receptors releases 
prostaglandins into the synaptic cleft, which inhibit neurotransmitter release through 
calcium-mediated negative feedback to the presynaptic neuron (Gross et al. 1977, Molderings et 
al. 1992, Gomez-Nino et al. 1992). Sympathetic (and parasympathetic) stimulation releases 
prostaglandins, probably synthesized in the postsynaptic effector cell de novo (Sherbourne et al. 
1992); PGE2 may inhibit the presynaptic release of norepinephrine (Wolfe and Horrocks 1993, 
Racke et al. 1992). However, Negishi and Ito (1992) reported that PGE2 induced catecholamine 
secretion from cultured bovine adrenal chromaffin cells. Catecholamines, acting as cosubstrates, 
stimulate prostaglandin synthesis and release, but inhibit leukotriene synthesis (Alanko et al. 
1992, Nadasy et al. 1992). Regulation of prostaglandin production in rat brain requires intact 
central adrenergic function (Weidenfeld et al. 1992). The MAO inhibitor tranylcypromine inhibits 
prostacyclin synthetase (Xiang and McNeil 1992). Central prostaglandins may provide the 
mechanism for catalepsy (Ono et al. 1992). In the hypothalamus, norepinephrine releases PGE2, 
mediated by nitric oxide (Rettori et al. 1992). The prostaglandins modulate pituitary hormone 
release by modulating dopamine (and other neurotransmitter) release; for example, PGD2 induces 
LH release (Wolfe and Horrocks 1993). 
Prostaglandins, especially PGE1, also raise cyclic AMP and cyclic GMP activity 
postsynaptically (Horrobin and Manku 1990, Rettori et al. 1992), an effect inhibited by opioids 
(Wolfe and Horrocks 1993). Some animal studies also have suggested interaction of 
prostaglandins and serotonin, another neurotransmitter sometimes implicated in ADHD and other 
psychiatric disorders; for example, PGD2 increases brain serotonin content and turnover (Wolfe 
and Horrocks 1993). Further, PGD2 in the preoptic hypothalamus induces sleep (Hayaishi 1991) 
while PGE2 induces wakefulness. 
In view of these biochemical findings, we might suspect that there may be some behavioral 
effects of dietary intake of the different lipids. 
Behavioral Effects in Animal Studies 
While most animal studies of dietary fat manipulation focus on biochemical, caloric, food 
choice, and body weight effects, there have been some provocative observations of learning and 
other behaviors. As compared to a 20% lard (saturated fat) diet, an otherwise identical 20% 
soybean-oil (polyunsaturated) diet results in improved learning on a variety of tasks, increased 
pain tolerance, increased preference for carbohydrate over protein, and increased exploratory 
activity in rats (Yehuda and Carasso 1987, Yehuda et al. 1986, Coscina et al. 1986, Greenwood 
and Winocur 1990). The improved learning appeared within 3 weeks and was transiently resistant 
to extinction. It could not be explained by basal body temperature, activity level, energy 
consumption, body weight, or brain choline acetyltransferase levels (Coscina et al. 1986). The 
improved learning apparently depends on a balance between Ω3 and Ω6 essential fatty acids (as 
found in soybean oil), not just essential fatty acids in general: Bourre et al. (1989) found that a 
sunflower-oil diet (highly polyunsaturated but only Ω6; poor in Ω 6 essential fatty acids) actually 
impaired shuttle-box learning. 
Enslen et al. (1991) report an interesting developmental implication. Four-month-old rats 
whose mothers had been gestationally fed either a 6% soybean-oil (balanced Ω3 and Ω6 essential 
fatty acids) diet or an otherwise identical 5.5% safflower-oil (rich in Ω6, poor in Ω3 essential fatty 
acids) diet were compared behav-iorally and histochemically. The total polyunsaturated 
22-carbon fatty acids in synaptic membrane and myelin phospholipids were the same for 
both-conditions, but the ratio of 22:6 Ω3 to 22:5 Ω 6 was significantly decreased in the 
safflower-oil-gestated rat brains. The safflower-oil rats also showed significantly lower 
exploratory behavior in novel environments. Feeding soybean-oil diets from weaning on could 
correct the brain phospholipid 22:6 Ω3-to-22:5 Ω6 ratio, but could not normalize the reduced 
exploratory behavior, suggesting a specific developmental need. 
Gamma-Linolenic Acid and Attention-Deficit Hyperactivity Disorder 
Some children are hypothesized to be deficient in delta-6-desaturase, which converts 
dietary linoleic acid (C18:2Q6) to gamma-linolenic acid (GLA, C18:3Q6), the precursor of 
dihomo-gamma-linolenic acid (dihomo-GLA, DHGLA, C20:3Q6), the only precursor for 
prostaglandin series-1. Widespread infantile vulnerability of this enzyme in the human species is 
suggested by the relatively large amount of GLA in human milk (Gibson and Kneebone 1981) as 
compared to other species, such as goats and cows. The fact that it is not present in all species 
suggests a selective evolutionary value, with active secretion rather than leak from the blood. 
Thus, it is reasonable to suspect that many human infants have immature delta-6-desaturation 
(which is compensated for by the presence of GLA in mother's milk). Taylor and Wadsworth 
(1984), reporting a slight but statistically significant cognitive and behavioral advantage of 
breast-fed over bottle-fed infants, speculated that one explanation might be that"... particular 
constituents of human milk may provide particular nutrients which allow optimal development of 
the human brain ..." (p. 78). Some children may have later maturation than others, resulting in 
symptoms associated with prostaglandin series-1 and possibly series-2 delta-6-desaturase 
deficiency. Because of the interactions between prostaglandins and catecholamine transmission 
described above, such relative deficiency states might cause symptoms of disorders that involve 
catecholamine aberrations, such as ADHD (Colquhoun and Bunday 1981). Supplementation with 
GLA should bypass defective delta-6-desaturation and correct such hypothesized relative 
deficiencies. 
Colquhoun and Bunday (1981) reported, in an open study, an apparent benefit of GLA in 
treating children with ADHD. We have reported (Arnold et al. 1989) a double-blind 
placebo-controlled crossover comparison of GLA supplementation to dextroamphetamine in 18 
boys with ADHD. All 3 treatment conditions showed a significant difference from each other on 
the hyperactivity factor of the Conners 39-item teacher rating, and showed a similar but 
nonsignificant trend on other measures. Overall, these trends suggested a possible benefit of GLA 
use, but the effect appeared smaller than with dextroamphetamine treatment. Mitchell et al. (1987) 
reported significantly lower levels of serum dihomo-GLA (20:3Q6, precursor of series-1 
eicosanoids), arachidonic acid (20:4 Ω 6, precursor of series-2 eicosanoids), and docosahexaenoic 
acid (22:6 Ω3) in 48 hyperactive children than in 49 age- and sex-matched controls. However, 
Aman et al. (1987) failed to find significant correlations of baseline blood lipids and behavior 
ratings in hyperactive children. 
To the best of our knowledge, no investigators have previously examined the correlation of 
blood lipids and behavior during treatment in a double-blind placebo-controlled crossover study. 
If essential fatty-acid metabolism and GLA supplementation truly affect behavior, we should 
expect significant correlations (regardless of treatment conditions) between behavioral scores and 
measures of body essential fatty-acid status. More specifically, delta-6-desaturase is the 
rate-limiting step in the synthesis of GLA (Horrobin and Manku 1990, Sprecher 1982, Brenner 
1982): If defective delta-6-desaturation of linoleic acid is an enzymatic bottleneck that is 
contributing to behavior problems, we would expect that (across conditions) behavior problems 
would correlate significantly with GLA (the product of delta-6-desaturation) but not with linoleic 
acid (the substrate). Behavior should also correlate significantly with the ratio of GLA (the 
downstream metabolite) to linoleic acid (the precursor). We report here a pilot exploration of this 
hypothesis. 
Method 
The subjects of this pilot exploration were a convenience sample in a previously reported 
(Arnold et al. 1989) double-blind completely counterbalanced double-crossover study of 18 
ADDH boys age 6-12 (mean and median age 9) comparing one month each of placebo, 
dextroamphetamine, and GLA supplementation. All subjects had a diagnosis of ADHD by 
DSM-III criteria (determined clinically by a child psychiatrist), normal intelligence, a score of 18 
or more on the Conners 10-item Hyperactivity Index, a sum of 24 or more on the first 6 items of 
the Davids Hyperkinetic Rating Scale (Davids 1971), no history of seizures, and no psychoactive 
drug in the preceding week. 
The GLA was administered in the form of Effamol™ capsules, each containing 500 mg 
evening primrose oil, including 350 mg linoleic acid and 40 mg GLA. The dose of Effamol™ was 
four capsules twice daily at breakfast and supper; it furnished a total daily dose of 320 mg of GLA. 
It was assumed that, with the wide availability and variation of linoleic acid in the ordinary 
American diet, the additional 2.8 grams of linoleic acid would not in itself produce a significant 
behavioral effect; so its presence in the Effamol™ was presumed to be inert. The dose of 
dextroamphetamine (either a 10- or 15-mg time-released spansule administered at breakfast) was 
selected to provide between 0.35 mg and 0.70 mg/kg daily. Informed permission of the parents 
and the assent of the child were obtained. 
The behavioral results were previously reported (Arnold et al. 1989). This report focuses 
on the blood lipid correlations with behavior. 
Blood samples were collected before breakfast, at baseline and/or at the end of various 
treatment conditions, from 16 of the 18 original subjects. Blood draw was optional for extra 
payment each time; most subjects agreed every time; 1 declined at baseline but agreed later; some 
who agreed at baseline declined later; on a few occasions venipuncture was unsuccessful. The 
serum was separated and frozen at -20°C for 2 years until analysis could be arranged at the 
laboratory of author R. A.G. Unfortunately, some of the specimens were lost. 
Samples were extracted in 2:1 chloroform/methanol containing butylated hydroxyanisole 
(0.005% w/v) according to the method of Bligh and Dyer (1959). Lipid classes were separated 
from the total extracted lipids by thin-layer chromatography on silica-gel H plates developed in 
petroleum ether/diethyl ether/acetic acid (90:15:1 by volume). Bands containing total 
phospholipids, triglycerides, and cholesterol esters were scraped into vials containing 5 ml 1% 
(v/v) sulfuric acid in methanol and the constituent fatty acids methylated by heating at 70°C for 3 
hours. The resulting fatty-acid methyl esters were extracted into heptane and analyzed by capillary 
gas chromatography (Hewlett-Packard HP 5880 gas Chromatograph). The 50-meter glass column 
(0.56 mm I.D.) was coated with SP2340 (Supelco Inc., Bellefonte, PA) by Chromalytic 
Technology Limited (Boronia, Victoria, Australia). The esters were separated using a carrier 
helium flow of 30 cm/see Avith a temperature gradient of 120°C to 200°C at 5°C per minute. The 
injection/split temperature was 250°C and the detector (F.I.D.) temperature was 300°C. Fatty-acid 
methyl esters were identified against authentic lipid standards obtained from Nuchek Prep, Inc. 
(Elysian, Minnesota). Results were stated as percent of total fatty acids represented by linoleic 
acid, GLA, and DHGLA, respectively. This was done separately for serum triglycerides, 
phospholipids, and cholesterol esters. 
Percentages of each fatty acid were correlated with concomitant behavior ratings. 
Spearman's correlations (SAS) were used to guard against skew by outliers. 
To screen for a possible metabolic bottleneck at the rate-limiting enzyme 
(delta-6-desaturase), ratios were calculated of the amounts of the downstream metabolites to the 
amounts of the precursor linoleic acid. These ratios were then examined for correlation with the 
behavior ratings, in the same way as described with the raw percentages of each fatty acid. This 
was done for the ratio of metabolite GLA to precursor linoleic acid (GLA/linoleic) as well as for 
the ratio of the sum of GLA and dihomo-GLA to linoleic acid (GLA+ DHGLA/linoleic). 
For some specimens the GLA level was below the detection threshold of 0.05%. This 
problem, along with missing specimens (storage errors, random across conditions), reduced the N 
for many single-condition correlations to single digits. Therefore, attention was focused on 
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